News

Show
news from

Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting

Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma

Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma

Anaveon appoints Dr Eduard Gasal as Chief Medical Officer

Anaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual Meeting

Anaveon announces upcoming poster presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

Load more

Search